Background It has been shown that successful reperfusion of the infarct-related artery by thrombolysis can prevent left ventricular dilation after acute myocardial infarction; these beneficial effects were detected from several days to several months after infarction. To date, however, no study has shown that these effects can be demonstrated within hours after the onset of infarction. Furthermore, data are scarce on the independent impact of thrombolytic therapy and late vessel patency on ventricular volume and function. The aim of this study was to assess separate effects of thrombolysis and patency of the infarct-related artery on left ventricular size and function by serial two-dimensional echocardiographic examinations.
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Methods and Results We evaluated 131 consecutive patients with first acute myocardial infarction by two-dimensional echocardiography in the following sequence: days 1, 2, 3, 7, and after 3 and 6 weeks. Intravenous streptokinase was administered in 81 patients, and 50 patients were treated without thrombolysis. Left ventricular end-diastolic volume, end-systolic volume, and ejection fraction were determined from apical two-and four-chamber views using the Simpson biplane formula and normalized to body surface area. Coronary angiography was performed in 107 patients after a mean of 26.0±20.2 (mean±SD) days after infarction. Patency of the infarct-related artery was assessed using TIMI criteria, with 54 considered patent (TIMI 3) and 53 with TIMI grade <3. On day 1, end-systolic volume was significantly higher in patients not receiving thrombolysis (37.7±15.3 versus 33.0±10.6 mL/ mi2, P=.045). End-systolic volume (ESVi) was significantly higher in patients treated without thrombolysis throughout the study, whereas significant differences in end-diastolic volume (EDVi) were detected from day 3 (P=.041) onward and in ejection fraction (EF) from day 2 (P=.025) onward, all differences becoming progressively more significant with time (6- Only four patients underwent revascularization during the time of the study: two angioplasties on days 13 and 29 and two coronary bypass operations on days 34 and 40. Each of the thrombolysis (T)/patency (P) subgroups (T+P+, T+P-, T-P+, and T-P-) was represented by one patient who was revascularized. Because of the small number of procedures and the few echo examinations occurring subsequent to them, revascularization was not included in the analysis.
Statistical Analysis
Unpaired t tests were used to assess the univariate effect of thrombolysis, patency of the infarct-related artery, and infarct location on left ventricular size and function at each point of time. ANOVA with repeated measurement was used to assess the independent impact of thrombolysis and vessel patency of left ventricular volume and function. This also supplied data on the timing of the impact, since the between-subjects differences would relate to overall ventricular volumes, whereas the within-subjects differences would relate to volume changes during the 6-week period of observation.
Temporal Analysis
To better utilize the temporal nature of the data, a two-stage linear regression model was used, analyzing in turn each of the systolic function indices. For example, end-systolic volume was modeled as follows. ESVijldt = aijkd+bijklt + eijkit' where i represents patient number, j represents thrombolysis (0=no, 1 =yes), k represents vessel patency at catheterization (TIMI 0 to 2=0; TIMI 3=1), and 1 represents infarct location (0=inferior, 1=anterior). a and b are, respectively, the intercept and slope for the linear regression of end-systolic volume for each subgroup, t is the follow-up time, and E is assumed to be a randomly distributed Gaussian error term. To convert the temporal sampling to a more normal distribution, the logarithm (base 2) of the day number was used instead of the actual day number. An additional benefit of this was that the intercept of the regression line would closely relate to initial (day 1) volumes, since log2 (1) Table 2 , left). End-diastolic volume index was similar in patients treated with and without thrombolysis on days 1 and 2 but became significantly higher in patients treated without thrombolysis on day 3; this difference became increasingly significant throughout the study (Fig 1, bottom; Table 3 , left). Ejection fraction was higher in patients receiving thrombolysis from admission to the end of the study (Fig 1, top; Table 4 , left).
Patency of the Infarct-Related Artery End-systolic volume index was significantly higher in patients with an occluded infarct-related artery from day 2, remaining higher over 6 weeks (Fig 2, middle ; Table 2 , middle). End-diastolic volume was similar in both groups until 3 weeks, when significantly higher end-diastolic volumes were detected in patients with an occluded infarct-related artery (Fig 2, bottom; Table 3 , middle). Ejection fraction was higher in patients with a patent artery from day 2, and the difference remained significant over the study period (Fig 2, top; and infarct extension. 15 Most importantly, their study demonstrated that infarct expansion can be detected within 24 hours from the onset of infarction.
The current study showed that left ventricular endsystolic volume was the most sensitive index of changes in ventricular geometry, demonstrating differences between thrombolytic subgroups as early as day 1, in accordance with the prior observation that end-systolic volume is the major determinant of survival after myocardial infarction.8 Although most thrombolytic trials have used ejection fraction to assess left ventricular function after the intervention, it seems clear that serial assessment of left ventricular volume provides better insight into left ventricular systolic function after myocardial infarction. 16 Prior Studies of Ventricular Function After Thrombolytic Therapy Jeremy et a117 have shown that patency of the infarctrelated artery had a significant impact on left ventricular size 1 month after infarction in patients treated with conventional therapy; the same group18 demonstrated that left ventricular dilation may continue over 6 months. The effect of thrombolytic therapy on left ventricular dilation was also evaluated in the GISSI study,6 which showed that end-diastolic and end-systolic volumes at discharge and 6 months later were lower in patients treated with thrombolytic therapy. Lavie et als have found in patients receiving thrombolysis that successful reperfusion was associated with lower left ventricular volume 6 weeks after infarction. Recently, Leung and Lau2 have assessed the influence of the degree of residual stenosis of the infarct-related artery after thrombolysis on left ventricular dilation determined 1 week, 6 months, and 1 year after infarction. They found no differences in end-diastolic volume between patients with minimal lesion diameter of 0 mm (completely occluded), <1.5 mm, and k1.5 mm at the initial measurement, but subsequently progressive increase of end- Day T-P-T-P+ T+P-T+P+ T-P-T-P+ T+P-T+P+ T-P-T-P+ T+P-T+P Finally, our data demonstrate an interesting discordance between the timing of benefit of thrombolysis and vessel patency. Throughout several types of statistical analyses, we showed that thrombolysis has its primary impact on initial ventricular volumes, whereas vessel patency relates primarily to subsequent dilation. This is shown most clearly in the two-stage linear regression model (Table 6) , where thrombolysis-not patencyhas a significant impact on the data intercept (corresponding to day 1), whereas patency has the overwhelming effect on the slope of the data (subsequent change). Impact of Infarct Location Important differences were seen in this study between patients with inferior versus anterior infarctions. Overall, we observed ventricular enlargement primarily in patients with anterior infarctions, consistent with the prior clinical'5 and experimental22 observations that inferior infarcts are usually small and rarely associated with ventricular dilation. It is thus not surprising that the major benefit we observed from both thrombolysis and vessel patency was in patients with anterior infarctions. In particular, the small number of patients (n=4) with anterior infarctions who failed to reperfuse after thrombolysis showed a particularly striking degree of dilation, with ESVi rising from 43.2 mL/m2 on day 1 to 66.4 mL/m2 at 6 weeks.
Limitations
The major limitation of the study is that the patients were not randomized to receive thrombolytic therapy but rather were assigned on the basis of their time to presentation to the hospital and the wishes of their attending cardiologist. Given the wealth of prior studies demonstrating the clinical efficacy of thrombolytic therapy in acute myocardial infarction, it would have been unethical to randomize these patients to placebo. 
